S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY

• Monica Carpenedo,
• Catherine M Broome,
• Vickie Mcdonald,
• Yoshitaka Miyakawa,
• David Kuter,
• Hanny Al-Samkari,
• James Bussel,
• Filip Matthijssens,
• Anna Hultberg,
• Jaume Ayguasanosa Dachs,
• Kristof De Beuf,
• Francesco Rodeghiero,
• Marc Michel,
• Adrian Newland

Affiliations

Monica Carpenedo

1 U.O.C Hematology and Transplant Unit Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy

Catherine M Broome

2 Georgetown University, Washington, United States

Vickie Mcdonald

3 Barts Health NHS Trust, London, United Kingdom

Yoshitaka Miyakawa

4 Saitama Medical University Hospital, Saitama, Japan

David Kuter

5 Massachusetts General Hospital, Hematology Division, Boston, United States

Hanny Al-Samkari

5 Massachusetts General Hospital, Hematology Division, Boston, United States

James Bussel

6 Weill Cornell Medical College, New York, United States

Filip Matthijssens

7 argenx, Ghent, Belgium

Anna Hultberg

7 argenx, Ghent, Belgium

Jaume Ayguasanosa Dachs

7 argenx, Ghent, Belgium

Kristof De Beuf

7 argenx, Ghent, Belgium

Francesco Rodeghiero

8 Haematology Project Foundation, Affiliated to the Department of Haematology, S. Bortolo Hospital, Vicenza, Italy

Marc Michel

9 Department of Internal Medicine, National Reference Center for Immune Cytopenias, Henri Mondor University Hospital, Assistance Publique–Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France

Adrian Newland

10 Centre for Haematology, Barts and the London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom